Skip to content
2000
image of Mucosal Melanoma: Treatment Strategies for a Heterogeneous Disease

Abstract

Mucosal melanoma (MM) is a potentially lethal malignant neoplasm arising in the respiratory, gastrointestinal, and urogenital tracts. MM comprises less than 2% of all melanomas, and no increase in its incidence has been reported. The etiopathogenesis of mucosal melanoma is uncertain. Whenever feasible, complete surgical excision is the treatment of choice for patients with regional disease. The clinical utility of routine lymph node sampling and completion lymph node dissection in patients with mucosal melanoma remains uncertain. Immune checkpoint inhibitors have become the standard-of-care for cutaneous melanoma. However, the biology of MM differs from that of cutaneous melanoma. Thus, the intensity of the response of MM is somewhat lower than that of cutaneous melanoma. This editorial highlights the recent advances in the treatment of mucosal melanoma.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128384909251102181721
2026-01-16
2026-01-27

  • From This Site

    /content/journals/cpd/10.2174/0113816128384909251102181721
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Mihajlovic M. Vlajkovic S. Jovanovic P. Stefanovic V. Primary mucosal melanomas: A comprehensive review. Int. J. Clin. Exp. Pathol. 2012 5 8 739 753 [PMID: 23071856
    [Google Scholar]
  2. Lerner B.A. Stewart L.A. Horowitz D.P. Carvajal R.D. Mucosal melanoma: New insights and therapeutic options for a unique and aggressive disease. Oncology (Williston Park) 2017 31 11 e23 e32 29179253
    [Google Scholar]
  3. Tyrrell H. Payne M. Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag. 2018 5 3 MMT11 10.2217/mmt‑2018‑0003 30459941
    [Google Scholar]
  4. Chang A.E. Karnell L.H. Menck H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 1998 83 8 1664 1678 10.1002/(SICI)1097‑0142(19981015)83 9781962
    [Google Scholar]
  5. Arondekar B. Curkendall S. Monberg M. Economic burden associated with adverse events in patients with metastatic melanoma. J. Manag. Care Spec. Pharm. 2015 21 2 158 164 10.18553/jmcp.2015.21.2.158 25615005
    [Google Scholar]
  6. Bedikian A.Y. Johnson M.M. Warneke C.L. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J. Immunotoxicol. 2008 5 2 201 207 10.1080/15476910802131519 18569391
    [Google Scholar]
  7. Kim K.B. Sanguino A.M. Hodges C. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004 100 7 1478 1483 10.1002/cncr.20113 15042682
    [Google Scholar]
  8. Bartell H.L. Bedikian A.Y. Papadopoulos N.E. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008 30 12 1592 1598 10.1002/hed.20910 18798304
    [Google Scholar]
  9. Yentz S. Lao C.D. Immunotherapy for mucosal melanoma. Ann. Transl. Med. 2019 7 S3 S118 10.21037/atm.2019.05.62 31576325
    [Google Scholar]
  10. Nassar K.W. Tan A.C. The mutational landscape of mucosal melanoma. Semin. Cancer Biol. 2020 61 139 148 10.1016/j.semcancer.2019.09.013 31655118
    [Google Scholar]
  11. Shoushtari A.N. Munhoz R.R. Kuk D. The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma. Cancer 2016 122 21 3354 3362 10.1002/cncr.30259 27533633
    [Google Scholar]
  12. Hamid O. Robert C. Ribas A. Antitumour activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-001, 002, 006. Br. J. Cancer 2018 119 6 670 674 10.1038/s41416‑018‑0207‑6 30202085
    [Google Scholar]
  13. Prior I.A. Lewis P.D. Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012 72 10 2457 2467 10.1158/0008‑5472.CAN‑11‑2612 22589270
    [Google Scholar]
  14. D’Angelo S.P. Larkin J. Sosman J.A. Efficacy and safety of Nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: A pooled analysis. J. Clin. Oncol. 2017 35 2 226 235 10.1200/JCO.2016.67.9258 28056206
    [Google Scholar]
  15. Nilsson P.J. Ragnarsson-Olding B.K. Importance of clear resection margins in anorectal malignant melanoma. Br. J. Surg. 2010 97 1 98 103 10.1002/bjs.6784 20013935
    [Google Scholar]
  16. Saleh M. Javadi S. Elsherif S. Multimodality Imaging and genetics of primary mucosal melanomas and response to treatment. Radiographics 2022 42 2 E81 10.1148/rg.229005 35230922
    [Google Scholar]
  17. Kalinsky K. Lee S. Rubin K.M. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607). Cancer 2017 123 14 2688 2697 10.1002/cncr.30663 28334439
    [Google Scholar]
  18. Andersen R. Donia M. Ellebaek E. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 2016 22 15 3734 3745 10.1158/1078‑0432.CCR‑15‑1879 27006492
    [Google Scholar]
  19. Forget M.A. Haymaker C. Hess K.R. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: Response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin. Cancer Res. 2018 24 18 4416 4428 10.1158/1078‑0432.CCR‑17‑3649 29848573
    [Google Scholar]
  20. Radvanyi L.G. Bernatchez C. Zhang M. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2012 18 24 6758 6770 10.1158/1078‑0432.CCR‑12‑1177 23032743
    [Google Scholar]
  21. Besser M.J. Shapira-Frommer R. Itzhaki O. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 2013 19 17 4792 4800 10.1158/1078‑0432.CCR‑13‑0380 23690483
    [Google Scholar]
  22. Kluger H Grigoleit GU Thomas S Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond) 2025 10.1002/cac2.70050
    [Google Scholar]
  23. Hayward N.K. Wilmott J.S. Waddell N. Whole-genome landscapes of major melanoma subtypes. Nature 2017 545 7653 175 180 10.1038/nature22071 28467829
    [Google Scholar]
  24. Kim K.B. Alrwas A. Treatment of KIT-mutated metastatic mucosal melanoma. Chin Clin Oncol 2014 3 3 35 5 25841461
    [Google Scholar]
  25. Satzger I. Schaefer T. Kuettler U. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br. J. Cancer 2008 99 12 2065 2069 10.1038/sj.bjc.6604791 19018266
    [Google Scholar]
  26. Gong H.Z. Zheng H.Y. Li J. The clinical significance of KIT mutations in melanoma: A meta-analysis. Melanoma Res. 2018 28 4 259 270 10.1097/CMR.0000000000000454 29746316
    [Google Scholar]
  27. Mattei J. Trindade E.N. Chedid M.F. Mucosal melanoma: From molecular landscape to current treatment strategies. Melanoma Res. 2023 33 6 447 453 10.1097/CMR.0000000000000916 37650711
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128384909251102181721
Loading

  • Article Type:     Editorial
Keywords: anti-PD1 ; pembrolizumab ; Mucosal melanoma ; diagnosis ; surgery ; chemotherapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test